Center for Cancer Policy and Program Evaluation (CarPE)
About the Center
We leverage the diverse research expertise of Institute researchers, use and expand our large population-based electronic and other data resources, and actively collaborate with partners in the U.S. and with colleagues in other countries.
The Institute has been a long-standing home for population-level cancer research and was a founding member of the HMO Cancer Research Network and the Dana/Farber Harvard Cancer Center. Our researchers come from several Institute divisions and external institutions.
Research
Cancer Research Areas
Disasters pose a threat to the health and health care of cancer patients and impact their communities. Our work aims to assess the type of threats faced by these populations and strategies to mitigate effects.
Most new cancer drugs come to markets with uncertain evidence of benefit that is not well communicated. We collaborate on interdisciplinary research to enable patients, prescribers, and payers to make evidence-based decisions consistent with their values.
Regulators seek to balance fast market access for cancer treatments and sound evidence of benefits and harms of these treatments. With US and international colleagues, we evaluate cancer drug regulations in the US, China, European countries and elsewhere.
The FDA utilizes the Sentinel initiative to surveil the safety of treatments among cancer patients and the risk of malignancies associated with non-cancer treatments.
High cancer drug prices impede access to and affordability of cancer treatments for patients and challenge payers and health systems. We assess the impacts of policies on cancer drug access, use, spending, and affordability among diverse populations.
Our Team

Join our team!
We embody a wide collection of talents, expertise, and backgrounds, cultivating a dynamic and collaborative environment.